Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.63 |
| ▸ | CTSB | P07858 | 6/20 | 0.63 |
| ▸ | CTSL | P07711 | 3/20 | 0.63 |
| ▸ | CTSS | P25774 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | PSMB5 | P28074 | 3/20 | 0.60 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.58 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.58 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29421135 | 1.00 | CASP3 (0.63) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL30697417 | 1.00 | CASP3 (0.63) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL7055973 | 0.99 | CASP3 (0.62) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL7141459 | 0.90 | CASP3 (0.64) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL8584619 | 0.90 | CASP3 (0.64) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL14341578 | 0.90 | PSMB1 (0.61) | CASP3CTSBCTSLCTSSPSMB5 | |
| SCHEMBL7050047 | 0.89 | CASP3 (0.63) | CASP3CTSBCTSLCTSSMEN1 | |
| SCHEMBL29421136 | 0.88 | REN (0.59) | CASP3CTSBCTSLPSMB5PSMB1 | |
| SCHEMBL14886926 | 0.88 | REN (0.59) | CASP3CTSBCTSLPSMB5PSMB1 | |
| SCHEMBL23644902 | 0.87 | CASP3 (0.57) | CASP3CTSBCTSLCTSSMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330116-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-10-19 | — | — | US | disclosed |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-06-13 | — | — | US | disclosed |
| US-20200368259-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200368259-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | SOST, TSG101, BST2 | CASP3 264/4885CTSB 400/4885CTSL 1311/4885 |
| US-11672811-B2 | Materials and methods for suppressing and/or treating bone related diseases and symptoms | SOST, TSG101, BST2 | CASP3 264/4885CTSB 400/4885CTSL 1311/4885 |
| US-20230330116-A1 | MATERIALS AND METHODS FOR SUPPRESSING AND/OR TREATING BONE RELATED DISEASES AND SYMPTOMS | SOST, TSG101, ACP3 | CASP3 288/4885CTSB 334/4885CTSL 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.